RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION
SINGAPORE, Dec. 7, 2025 /PRNewswire/ — AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute... Read more.
Linux Foundation Welcomes Mitsubishi Electric as Gold Member During Open Source Summit Japan
Mitsubishi Electric’s membership upgrade from silver establishes the manufacturer as an active contributor to open source and critical presence in software... Read more.
AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore
SINGAPORE, Dec. 7, 2025 /PRNewswire/ — ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and... Read more.
Linux Foundation Research Releases New Report: “The State of Open Source Japan 2025: Accelerating Business Value through Strategic Open Source Engagement”
TOKYO, Dec. 7, 2025 /PRNewswire/ — Open Source Summit Japan — The Linux Foundation, the nonprofit organization enabling mass innovation through open source,... Read more.
Anchorage Digital Integrates Middleware Provider BridgePort to Enhance Institutional Settlement Infrastructure
NEW YORK and SAN FRANCISCO, Dec. 7, 2025 /PRNewswire/ — Anchorage Digital, a crypto platform that provides institutions with integrated financial services... Read more.
Lilly’s Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically... Read more.
Replicor publishes data from its compassionate access program in HBV/HDV
MONTREAL, Dec. 7, 2025 /PRNewswire/ – Replicor Inc. announced the publication of data from its first global compassionate access program in the Journal of... Read more.
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
– 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX,... Read more.
The 4th China International Supply Chain Expo Set for Beijing in June 2026
Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/ — The 4th China International Supply Chain Expo... Read more.
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients... Read more.